Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease

European Journal of Clinical Investigation

Volumn 26, Issue 11, 1996, Pages 996-1003

  Murakami, T ^a   Komiyama, Y ^a   Masuda, M ^a   Kido, H ^a   Nomura, S ^a   Fukuhara, S ^a   Karakawa, M ^a   Iwasaka, T ^a   Takahashi, H ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

CD62P; CD63; Coronary artery disease; Flow cytometry; Platelet activation

Indexed keywords

CD63 ANTIGEN; PADGEM PROTEIN; THROMBOCYTE ANTIGEN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; THROMBOCYTE ACTIVATION;

EID: 0029855056     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.2360585.x     Document Type: Article

References (41)

1. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983-9.
2. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
3. Nilsson J, Volk-Jovinge S, Svensson J, Landou C, De Faire U, Hamsten A. Association between high levels of growth factors in plasma and progression of coronary atherosclerosis. J Intern Med 1992;232:397-404.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature 1993;362:801-9.
5. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989;80:1501-13.
6. Lewis HD, Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
7. Levine SP, Lindenfeld J, Ellis JB, Raymond NM, Krentz LS. Increased plasma concentrations of platelet factor 4 in coronary artery disease. Circulation 1981;64:626-32.
8. Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981;57:199-202.
9. Sobel M, Salzman EW, Davies GC et al. Circulating platelet products in unstable angina pectoris. Circulation 1981;63: 300-6.
10. Bellon JL, Castellanos C, Acevedo L, Amiral J. Measurement of beta-thromboglobulin and platelet factor 4 to follow up patients with artificial heart valves. Semin Thromb Hemost 1993; 19(suppl 1):178-82.
11. McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem 1984;259:9799-804.
12. Adelman B, Michelson AD, Handin RI, Ault KA. Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood 1985;66:423-7.
13. George JN, Pickett EB, Saucerman S et al. Platelet surface glycoproteins: Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986;78:340-8.
14. Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A Platelet alpha granule membrane protein that is associated with the plasma membrane after activation: Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest 1986;78:130-7.
15. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
16. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128-38.
17. Nieuwenhuis HK, van Oosterhout JJG, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosomal-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987;70:838-45.
18. Metzelaar MJ, Wijngaard PLJ, Peters PJ, Sixma JJ, Nieuwenhuis HK, Clevers HC. CD63 antigen: a novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991; 266:3239-45.
19. Corash L. Measurement of platelet activation by fluorescence-activated flow cytometry. Blood Cells 1990;160:97-108.
20. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-93.
21. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Comparison of platelet membrane markers for the detection of platelet activation in vitro and during platelet storage and cardiopulmonary bypass surgery. J Lab Clin Med 1993;121: 579-87.
22. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: flow cytometric detection. Arterioscler Thromb 1992;12:1475-87.
23. Tschoepe D, Schultheiß HP, Kolarov P et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993;88:37-42.
24. Austen WG, Edwards JE, Frye RL et al. AHA Committee Report: a reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975;51(suppl):5-40.
25. Nomura S, Kokawa T. Recent advance on analysis of antiplatelet antibody: special reference to application of flow cytometry. In: Okuda K, ed. Automation and New Technology in the Clinical Laboratory. Oxford: Blackwell Scientific Publications, 1990: 287-94.
26. Kerry PJ, Curtis AD. Standardization of β-thromboglobulin (β-TG) and platelet factor 4 (PF4): a collaborative study to establish international standards for β-TG and PF4. Thromb Haemost 1985;53:51-5.
27. Hourdillé P, Heilmann E, Combrié R, Winckler J, Clemetson KJ, Nurden AT. Thrombin induces a rapid redistribution of glycoprotein Ib-IX complexes within the membrane systems of activated human platelets. Blood 1990;76:1503-13.
28. Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991;31:409-14.
29. Reimers H-J, Kinlough-Rathbone RL, Cazenave J-P et al. In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemost 1976;35:151-66.
30. Cieslar P, Greenberg JP, Rand ML, Packham MA, Kinlough-Rathbone RL, Mustard JF. Separation of thrombin-treated platelets from normal platelets by density-gradient centrifugation. Blood 1979;53:867-74.
31. Johnston GI, Pickett EB, McEver RP, George JN. Heterogeneity of platelet secretion in response to thrombin demonstrated by fluorescence flow cytometry. Blood 1987;69:1401-3.
32. Ludlam CA. Evidence for the platelet specificity of β-thromboglobulin and studies on its plasma concentration in healthy individuals. Br J Haematol 1979;41:271-8.
33. Stewart ME, Douglas JT, Lowe GDO, Prentice CRM, Forbes CD. Prognostic value of beta-thromboglobulin in patients with transient cerebral ischemia. Lancet 1983;2:479-81.
34. Tschoepe D, Roesen P, Esser J et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991;17:433-8.
35. Devine DV, Andestad G, Nugent D, Carter CJ. Plateletassociated factor XIII as a marker of platelet activation in patients with peripheral vascular disease. Arterioscler Thromb 1993;13:857-62.
36. Ejim OS, Powling MJ, Dandona P, Kernoff PBA, Goodall AH. A flow cytometric analysis of fibronectin binding to platelets from patients with peripheral vascular disease. Thromb Res 1990;58:519-24.
37. Galt SW, McDaniel MD, Ault KA, Mitchell J, Cronenwett JL. Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease. J Vasc Surg 1991;14:747-56.
38. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood 1993;82:505-12.
39. Chronos NAF, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of α-granules or lysosomes from, human platelets. Clin Sci 1994;87:575-80.
40. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993;70:659-66.
41. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409-11.